Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

SellasgpsCurativeBAT9 May. 13 at 11:50 AM

$SLS $RVMD 1st Big pharmaceutical offer coming by EOW. Big pharmaceuticals are already regretting not picking up RVMD for $30 Billion they want make the same mistake here at SLS. ✌️🙏❤️‍🩹

0 · Reply

QuantInsider May. 13 at 12:20 AM

$RVMD looking like a tug-of-war right now Big June call blocks popping up, 3,777 contracts totaling about $1.96M in premium at the ask on InsiderFinance It's all around that 145 to 175 range, but don't jump the gun This might be a focus zone until more flow shows up On the flip side, RVMD missed EPS by $0.46 Still hanging near 12-month highs, but with a Street target way lower Plus, insider and Comerica Bank offloading shares near $150 Definitely some downside risk here If you're going long, maybe think about hedging or keeping it tight

0 · Reply

SellasgpsCurativeBAT9 May. 12 at 11:19 PM

$SLS $RVMD $ABVX Long Brothers and Sisters as I said earlier today Don’t step on hundred Dollar 💵 Bills to pick up Pennie’s. Have the Conviction to hold till $280.00+ it’s coming. ABVX + RVMD will look like child’s play when this moves it will be one ☝️ of the most violent uptick in the History of the Wall Street. ✌️🙏❤️‍🩹

0 · Reply

flabb May. 12 at 9:21 PM

$RVMD reduced 146.50 and i will come back tomorrow and add on pullbacks if she runs in the morning.

0 · Reply

OptionRunners May. 12 at 7:54 PM

Large roll in $RVMD calls into the close. $2.04M position but taking about $2.6M off the table.

2 · Reply

Jack_Nicholson_Truth May. 12 at 10:27 AM

$CHRS good catch! Also chrs ccr8 mirrors $RVMD! (if chs-114 is the most selective with no tox). Kras took decades and out of the kras drugs before, HAD THE LOWEST TOX SO IT COULD WORK AND PATIENT COULD STAY ON TRIAL! This is from today nytimes about kras.

0 · Reply

GregK13 May. 12 at 1:20 AM

$RVMD is it always so dead in here? And totally zero price movement after hours?

0 · Reply

Skoufc1 May. 11 at 11:44 AM

$RVMD Does RVMD get bought out or does it become the next regeneron or Vertex Pharma is the question?

2 · Reply

PeterLynch_IsBack May. 11 at 2:09 AM

$RVMD mean ass stage 2 uptrend ai said some bullish targets in 400s on approval. I mean its pretty close to approval if it this stuff is all true: The Three Main Drivers of Institutional Interest "Unprecedented" Clinical Breakthrough (April 2026) The Data: In the Phase 3 RASolute 302 trial, daraxonrasib nearly doubled the overall survival of metastatic pancreatic cancer patients (13.2 months) compared to standard chemotherapy (6.7 months). The Impact: Pancreatic cancer is famously difficult to treat; these results represent a 60% reduction in the risk of death, which analysts have called "practice-changing".

0 · Reply

JuggernautRaider May. 10 at 8:52 PM

$IMRX earnings coming monday 🤫 i tried to get @Duediligence20 to sell $PPBT and buy this when it was below a $1.25 last year; Tony is a friend but now I realize I should have had just bought more 😜 $RVMD better watch their ass 🚽 Immuneering is coming 🚊

2 · Reply

Revolution Medicines price target raised to $185 from $170 at BofA

2026-05-07T16:42:48.000Z - 5 days ago

Revolution Medicines price target raised to $172 from $120 at Piper Sandler

2026-05-07T10:48:40.000Z - 6 days ago

Revolution Medicines price target raised to $205 from $175 at Guggenheim

2026-05-07T01:25:33.000Z - 6 days ago

Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)

2026-05-07T01:23:10.000Z - 6 days ago

Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B

2026-05-07T00:22:46.000Z - 6 days ago

Revolution Medicines announces NEJM publication of data on Daraxonrasib

May 6, 2026, 6:00 PM EDT - 6 days ago

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

May 6, 2026, 5:01 PM EDT - 6 days ago

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

May 6, 2026, 4:30 PM EDT - 6 days ago

Revolution Medicines Earnings Call Transcript: Q1 2026

May 6, 2026, 4:02 PM EDT - 6 days ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 1, 2026, 12:54 PM EDT - 11 days ago

US FDA authorizes early access to Revolution's pancreatic cancer pill

2026-05-01T16:06:57.000Z - 11 days ago

FDA permits expanded access for Revolution pancreatic cancer drug

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Apr 28, 2026, 5:30 AM EDT - 15 days ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

2026-04-27T14:37:58.000Z - 15 days ago

Erasca believes Revolution infringement claims ‘without merit,’ says Stifel

ERAS

2026-04-27T13:58:48.000Z - 15 days ago

Erasca sinks after Revolution Medicines alleges patent infringement

ERAS

Apr 21, 2026, 5:35 PM EDT - 21 days ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Apr 21, 2026, 5:35 PM EDT - 21 days ago

Two experimental drugs showed striking early results against pancreatic cancer

BNTX

Apr 21, 2026, 5:30 PM EDT - 21 days ago

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Apr 21, 2026, 11:23 AM EDT - 21 days ago

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

2026-04-19T20:25:47.000Z - 23 days ago

Revolution Medicines to present updated Phase 1 data for zoldonrasib

Apr 19, 2026, 2:00 PM EDT - 23 days ago

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

Apr 17, 2026, 4:02 PM EDT - 25 days ago

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 15, 2026, 12:10 PM EDT - 27 days ago

This Pill May Help Pancreatic Cancer Patients Live Longer

2026-04-15T09:50:40.000Z - 4 weeks ago

Revolution Medicines 10.563M share Secondary priced at $142.00

Apr 15, 2026, 12:41 AM EDT - 4 weeks ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

2026-04-14T11:56:03.000Z - 4 weeks ago

Revolution Medicines price target raised to $200 from $140 at Evercore ISI

2026-04-14T11:51:09.000Z - 4 weeks ago

Revolution Medicines price target raised to $175 from $160 at Guggenheim

2026-04-14T11:25:01.000Z - 4 weeks ago

Revolution Medicines price target raised to $162 from $140 at RBC Capital

2026-04-14T10:10:12.000Z - 4 weeks ago

Revolution Medicines price target raised to $169 from $73 at H.C. Wainwright

2026-04-13T21:10:39.000Z - 4 weeks ago

Revolution Medicines files to sell $750M of common stock

2026-04-13T21:10:13.000Z - 4 weeks ago

Revolution Medicines files to sell $250M of convertible senior notes

Apr 13, 2026, 4:01 PM EDT - 4 weeks ago

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Apr 13, 2026, 10:13 AM EDT - 4 weeks ago

Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Apr 13, 2026, 9:45 AM EDT - 4 weeks ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.

Apr 13, 2026, 9:11 AM EDT - 4 weeks ago

This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.

Apr 13, 2026, 8:06 AM EDT - 4 weeks ago

Revolution Medicines' experimental cancer pill helps improve survival in late-stage study

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Apr 10, 2026, 1:49 PM EDT - 4 weeks ago

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Mar 17, 2026, 6:37 PM EDT - 2 months ago

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Mar 3, 2026, 9:50 AM EST - 2 months ago

Revolution Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:30 PM EST - 2 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:02 PM EST - 2 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb 24, 2026, 4:05 PM EST - 2 months ago

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:05 PM EST - 2 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb 11, 2026, 9:30 AM EST - 3 months ago

Revolution Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 3 months ago

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 26, 2026, 4:30 PM EST - 3 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK

Jan 25, 2026, 3:27 PM EST - 3 months ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

MRK

Jan 25, 2026, 2:30 PM EST - 3 months ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK

Jan 12, 2026, 1:30 PM EST - 4 months ago

Revolution Medicines Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 2:58 PM EST - 4 months ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

MRK

Jan 9, 2026, 5:54 AM EST - 4 months ago

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.

Jan 8, 2026, 3:56 PM EST - 4 months ago

Merck in talks to buy biotech Revolution Medicines, FT reports

MRK

Jan 8, 2026, 8:00 AM EST - 4 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Jan 8, 2026, 7:38 AM EST - 4 months ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

ABBV

Jan 7, 2026, 2:58 PM EST - 4 months ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

ABBV

Jan 7, 2026, 2:48 PM EST - 4 months ago

AbbVie Near Deal for Revolution Medicines

ABBV

Jan 5, 2026, 4:05 PM EST - 4 months ago

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 18, 2025, 4:30 AM EST - 6 months ago

Revolution Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 9:00 AM EST - 6 months ago

Revolution Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:02 PM EST - 6 months ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 4, 2025, 4:05 PM EST - 6 months ago

Revolution Medicines to Participate in November 2025 Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 6 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Oct 22, 2025, 12:12 PM EDT - 7 months ago

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Oct 16, 2025, 8:00 PM EDT - 7 months ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Sep 29, 2025, 9:00 AM EDT - 8 months ago

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Sep 10, 2025, 5:00 PM EDT - 8 months ago

Revolution Medicines Transcript: Study Result

Sep 10, 2025, 4:02 PM EDT - 8 months ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Revolution Medicines Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:02 PM EDT - 9 months ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Jul 30, 2025, 4:05 PM EDT - 10 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Jul 24, 2025, 4:00 PM EDT - 10 months ago

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Jul 9, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates

SellasgpsCurativeBAT9 May. 13 at 11:50 AM

0 · Reply

QuantInsider May. 13 at 12:20 AM

0 · Reply

SellasgpsCurativeBAT9 May. 12 at 11:19 PM

0 · Reply

flabb May. 12 at 9:21 PM

$RVMD reduced 146.50 and i will come back tomorrow and add on pullbacks if she runs in the morning.

0 · Reply

OptionRunners May. 12 at 7:54 PM

Large roll in $RVMD calls into the close. $2.04M position but taking about $2.6M off the table.

2 · Reply

Jack_Nicholson_Truth May. 12 at 10:27 AM

0 · Reply

GregK13 May. 12 at 1:20 AM

$RVMD is it always so dead in here? And totally zero price movement after hours?

0 · Reply

Skoufc1 May. 11 at 11:44 AM

$RVMD Does RVMD get bought out or does it become the next regeneron or Vertex Pharma is the question?

2 · Reply

PeterLynch_IsBack May. 11 at 2:09 AM

0 · Reply

JuggernautRaider May. 10 at 8:52 PM

2 · Reply

biolover May. 10 at 5:06 PM

$ERAS $MRK $PFE $RVMD

1 · Reply

ErosROI May. 10 at 2:54 PM

$RVMD I love the fact that we're getting new fans in here

1 · Reply

docsamiles May. 8 at 7:20 PM

$ERAS What is different between these drugs is the incidence and severity of drug rash. This is again seen with all three but the severity goes RVMD >> ERAS >> VSTM. For an example, see pictures of Ben Sasse. He's on $RVMD. The $RVMD and $ERAS drugs are indentical in cross reactivity to H-Ras as the binding site ligand is identical. The lower incidence and severity of rash seen with ERAS-0015 has to do with the increased potency relative to RVMD-6236 allowing doctors to use a lower dose. This in turn results in a lower exposure of the skin cells to the drug and less inhibition of H-ras (the mechanism of the rash). $VSTM's drug has a lower affinity for H-Ras resulting in even lower incidence of rash. This will ultimately be the marketing differentiator in the marketplace and why $ERAS will eventually pass $RVMD in sales. All three will sell a LOT of drug and make a lot of money. Remember though, the market's not always rational.

2 · Reply

Ro_Patel May. 8 at 6:24 PM

$GOOGL 13F $CME $PL $ASTS $RVMD

1 · Reply

BioRich May. 8 at 6:12 PM

$XBI Whoa! Trump wants Makary out? FDA Commish sent walking? Honestly, I watched the White House News Conference regarding psychadelics a few weeks ago and Trump was clearly questioning why it's taking so long to get drugs to people that need it and promoted his "Right to Try" promotion. Makary didn't look happy. If I can find the video, I'll share it. But I had a feeling that wasn't going to end well. So who benefits now? $CAPR I think is the clearest winner. $IBRX? $RVMD? Who y'all thinking? Follow/Subscribe for more suggestions and perspective. Would love to hear yours as well. That's how we find these gems and learn. Let's make some (more) money. Cheers! https://www.bloomberg.com/news/articles/2026-05-08/trump-plans-to-fire-fda-s-marty-makary-after-tumult-at-agency?utm_source=website&utm_medium=share&utm_campaign=copy

3 · Reply

Jackie_O_ May. 8 at 5:08 PM

$RVMD Welcome Google 🤗

0 · Reply

BioRich May. 8 at 3:01 PM

$CADL $TGTX $IBRX $RVMD $TLSA Who gets the BO first? My thoughts: 1) TGTX 2) RVMD 3) IBRX 4) CADL 5) TLSA Wouldn't be surprised to see BO news on any of these though. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

6 · Reply

flabb May. 8 at 2:58 PM

$RVMD 142.27 added becuase what is 4 points down not a big deal to catch that 138.35 if she goes to 146.37 from here . good to go.

0 · Reply

flabb May. 8 at 1:45 PM

$RVMD filled 29.56 on the opening and is now climnbing . $AISP 2.43 filled

0 · Reply

MorganHoratio May. 8 at 1:44 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: PayPay Corp (Tokyo-listed) - 3,125,000 $PL - 35,248,893 $PRME - 16,562,498 $RLAY - 1,564,173 $RVMD - 3,292,525 $SANA - 2,812,500 Google’s Q1 13F is here: Fintech, Real-time Earth, and Gene Editing! The 3.1M share stake in PayPay is a major power move into the East Asian payment ecosystem. Meanwhile, holding 35M shares of $PL (Planet Labs) signals that Google is weaponizing satellite data to give Gemini AI a "God’s eye view" of global logistics. Heavy bets on $PRME and $RVMD also prove that AI-driven oncology and gene editing are now core to Alphabet’s "Other Bets." Do you think the synergy between satellite data and fintech will lead to a breakthrough in 2026? Which of these strategic pivots are you most bullish on?

1 · Reply

flabb May. 8 at 12:48 PM

$RVMD i have to say has a shot at the 138.35 on the opening so if you like this soldier set your limit order there and if it goes lower add a share or two. I'll be accumulating until she bottoms but it wouldn't suck to catch the 138.35 order.

1 · Reply

flabb May. 8 at 11:09 AM

$RVMD 142.15 limit order in

1 · Reply

Market Cap	30.65B
Revenue (ttm)	0.00
Net Income (ttm)	-1.13B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	1,422,600
Avg Vol	2,990,804
Day's Range	N/A - N/A
Shares Out	212.60M
Stochastic %K	55%
Beta	1.41
Analysts	Strong Sell
Price Target	$181.30